Global Cardiac Risk Management Anthony Battad CD, MD, MSc., MPH, FRCPC Director // Directeur Ambulatory Care, St. Boniface Hospital // Soins ambulatoire,

Slides:



Advertisements
Similar presentations
Lipid Management in 2015: Risk & Controversies
Advertisements

Preventing Strokes One at a Time Acute Interventions and Management 2009.
Cardiovascular Diseases and Internal Medicine
Cardio-Metabolic Syndrome Guidelines on Education, Detection and Early Treatment  Heval Mohamed Kelli, PGY-2 Emory Internal Medicine Residency no conflict.
CVD risk estimation and prevention: An overview of SIGN 97.
Updated December 2005 PREVENT DIABETES AND HEART DISEASE Enjoy a healthy lifestyle and improve your health 1.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Canadian Diabetes Association Clinical Practice Guidelines Dyslipidemia Chapter 24 G. B. John Mancini, Robert A. Hegele, Lawrence A. Leiter.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
Lipids 101 Cardiology Board Review Med-Peds Style!
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Management of Hypertension according to JNC 7 BY SANDAR KYI, MD.
Morteza Naghavi, M.D. Founder Society for Heart Attack Prevention and Eradication (SHAPE) SHAPE Guidelines Prevention of Fatal Cardiovascular Events (Heart.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Ischemic Heart Diseases IHD
Cardiovascular Disease in Women Module III: Risk Assessment Tool.
LIFESTYLE MODIFICATIONS FOR PREVENTING HEART DISEASE [e.g. HEART ATTACKS] [ primary prevention of coronary artery disease ] DR S. SAHAI MD [Med.], DM [Card]
An Overview of the Alberta Screening & Prevention Initiative.
Metabolic Syndrome, Diabetes, and Cardiovascular Disease: Implications for Preventive Cardiology Nathan D. Wong, PhD, FACC, FAHA Professor and Director.
Tt HRB Centre for Health and Diet Research The burden of hypertension Ivan J Perry, Dept. of Epidemiology and Public Health, University College Cork. Institute.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Global impact of ischemic heart disease World Heart Federation, 2011.
Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation? July
Stroke Awareness & Prevention Suheb Hasan, MD Health Seminar MCWS November 17, 2012.
December Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation?
RISK FACTOR FOR CORONARY ARTERY DISEASE
METABOLIC Syndrome: a Global Perspective
Harmonizing Cardiovascular Risk Intervention Guidelines in Canada – The C-CHANGE Initiative February 6, 2013 Montreal, Quebec Harmonizing Cardiovascular.
Risk estimation and the prevention of cardiovascular disease SIGN 97.
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
CARDIOVASCULAR CARE of the OUTPATIENT Diane M. Enzweiler, MSN, ANP-BC St. Elizabeth Physicians: Heart and Vascular.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
Blood pressure control in primary health care WORKSHOP
Hypertension: Blood Pressure Measurement and the new NICE guideline Prof Richard McManus BHS Annual Meeting Cambridge 2011 NICE clinical guideline 127.
International Guidelines for Prevention of Atherosclerotic Cardiovascular Disease Prof. Mohamed Sobhy, MD, FACC Professor of Cardiology, Alex. University.
Group work 5 Hypertension case discussions. Objectives At the end of this session, the trainees should: Be able to explain steps of correct BP measurement.
Predictive Value of Coronary Calcium Scoring Matthew Budoff, MD, FACC, FAHA Associate Professor of Medicine UCLA School of Medicine Director, Cardiac CT.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
HYPERTENSION RECOMMENDATIONS FOR FOLLOW UP BASED ON INITIAL BP READING
Insulin Resistance Progression to Diabetes. Hypertension: BP >140/90 Dyslipidemia: ◦TG >150 mg/dL (1.7 mmol.L) ◦HDL-C
Section III. Assessment of Overall Cardiovascular Risk in Hypertensive Patients 2015 Canadian Hypertension Education Program Recommendations.
Cardiovascular Disease Risk Stratification
Identifying Persons in Need of Weight-loss Treatment: Evaluation of Potential Treatment Algorithms Caitlin Mason School of Physical and Health Education.
Monitoring Physical Health Stephen R. Marder, M.D. Professor, Semel Institute for Neuroscience and Human Behavior at UCLA Director, VA VISN 22 Mental Illness.
An aortic aneurysm can rupture (dissecting aneurysm) and cause massive blood loss, circulatory shock and rapid death.
2007 Hypertension as a Public Health Risk January, 2007.
Dyslipidemia CASE 5A. Aling D., 62 years old female who came in for a General Check-up General Data.
Laboratory Testing For Cardiovascular Risk
Ross T. Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC Yazid NJ Al Hamarneh, BPharm, PhD Charlotte Jones, MD, PhD, FRCP(C) Brenda Hemmelgarn, MD, PhD, FRCP(C)
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Scott W. Rypkema, M.D.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
PUTTING PREVENTION FIRST Vascular Checks Dr Bill Kirkup Associate NHS Medical Director.
NHS Health Check programme An opportunity to engage 15 million people to live well for longer Louise Cleaver National Programme Support Manager.
Case 1: Elevated LDL-C in a Young Adult. Page 2 of 10 *DALY; disability-adjusted life years Routine checkup:  Age:33 years  Sex: male  Status: Except.
Cardiovascular Risk: A global perspective
Cardiovascular Disease: Risk Factors and Risk Assessment
Management of Hypertension according to JNC 7
Redefining Quality Care in T2DM Patients with CV Disease
The role of unknown risk factors in coronary heart disease
Hypertension guidelines What’s all the controversy about 2015
Cholesterol practice questions
Diabetes Health Status Report
Type 2 diabetes: Overlap of clinical conditions
Rational Order of Laboratory Tests in Cardiovascular Diseases
Goals & Guidelines A summary of international guidelines for CHD
Cardiovascular Disease in Women Module III: Risk Assessment Tool
Preventative Cardiology
Insert Case Title Case Overview
Presentation transcript:

Global Cardiac Risk Management Anthony Battad CD, MD, MSc., MPH, FRCPC Director // Directeur Ambulatory Care, St. Boniface Hospital // Soins ambulatoire, Hôpital St. Boniface Medical Director //Directeur médical Master of Physician Assistant Studies // Mâitre d’études assitants-médicine University of Manitoba // Université du Manitoba

Disclosure Conference expenses paid for by University of Manitoba No financial conflicts to disclose

Understand the global impact of atherosclerotic disease Name the major risk factors implicated in atherosclerotic disease Recall the important targets for atherosclerotic risk factors Implement a global strategy for the prevention and treatment of atherosclerotic disease Objectives

64 year old male. Previously well (no PMHx) No family history of premature HD Non-smoker; Minimal ETOH use Took his blood pressure at Walmart 162/80 In the office: 156/78 (BP Tru) Remainder of exam is unremarkable Case # 1

56 year old female On a routine physical: LDL = 5, HDL = 1.02, TG = 2.4 No previous medical history FHx: (+) for HD on father’s side BMI = 29 BP = 146/56 Case # 2

55 year old male in for “executive physical” FHx: (+) for MI (father at 52, mother at 56) Smoker 12 pk-yrs; 8 – 10 drinks / week High stress job Case # 3

Not every person at high risk will develop disease Not every person at low risk will be event free Estimating the lifetime risk of CV disease can be difficult Most risk factor calculators underestimate or overestimate the risk Risk factor treatment to accepted targets have inherent risks Which asymptomatic patients do you target for screening? Global Risk Management: The Challenge

2013: 15.3 million deaths annually 1 Lifetime risk of CVD: 20 % – 49 % ♂ and 32 % ♀ 2 One half to one third of all CVD attributable to CHD/CAD Over 90% of all CHD events occur in patients with at least one risk factor The “Big 3” modifiable risk factors: Dyslipidemia Hypertension Diabetes Some facts to consider 1 The Farr Institute of Health Informatics Research, Jones, L., Framingham Study, 1999

HypertensionDyslipidemiaDiabetes Smoking

> 10 % CV deaths worldwide, 30 % North America Pathophysiology: Vasoconstriction  HTN Hypercoagulability  clot formation Endothelial dysfunction  vascular instability Single most effective intervention A few words about smoking

Some more facts… Canadians/year suffer an MI and /year suffer stroke 75% of stroke victims survive first event 33% of patients under the age of 65 Hospitalized MI has 8% mortality 1 in 2 MI patients are under the age of 65 ~ $19 billion/year cost to Canadian economy

Why is risk assessment and treatment needed? Who Cares !!!!

To identify individuals at sufficient risk so appropriate global intervention can be given LDL < 2 BP < 130/80 BMI < 26 A1C < 6 Excercise Smoking Cessation

It is NOT unique to any one population

3 Step Approach to Global Risk Management Screening: Who and When Stratify to Risk Group: High, Medium, Low Treat according to risk Specific, easy targets

Screening: Who and When Males ≥ 40 / Females ≥ 50 (or post-menopausal) All adults: DM, HTN, smoker, evidence of atherosclerosis, FHx of premature CAD, abdominal obesity When: PHE, routine office visit, even acute unrelated illness Screen with full lipid profile, FBG

Figure 1 Canadian Journal of Cardiology , DOI: ( /j.cjca ) Canadian Caridovascular Society, 2012

Figure 2 Canadian Journal of Cardiology , DOI: ( /j.cjca ) Canadian Caridovascular Society, 2012

Figure 3 Canadian Journal of Cardiology , DOI: ( /j.cjca ) Canadian Caridovascular Society, 2012

Stratify to a Risk Group High Risk: FRS > 19% or DM, proven CAD, PVD, CVD Medium Risk: FRS 10% - 19% Low Risk: FRS: < 10%

Patient Screened High Risk: LDL < 2 mmol/L BP < 130/80 FBG ≤ 7 Medium Risk: LDL < 3.5 BP <130/80 FBG ≤ 7 Low Risk: LDL < 5 BP and FBG as above Metabolic Syndrome WC > 102 cm male/ 88 cm female TG ≥ 1.7 mmol/L HDL ≤ 1 mmol/L male/ 1.3 female BP ≥ 130/85 FBG 6.2 – 7.0 mmol/L DM or CAD/Surrogates? NoYes

Figure 4 Canadian Journal of Cardiology , DOI: ( /j.cjca ) Canadian Caridovascular Society, 2012

Targets: Summary Lipid Profile:  Risk: < 2 mmol/L and TC/HDL ratio < 4  Risk: < 3.5 mmol/L (ratio < 5)  Risk: < 5 mmol/L (ratio < 6) Fasting Blood Glucose: < 7 mmol/L (or < 6 if tolerated)

PopulationSBP >DBP > Diabetes13080 High risk (TOD or CV risk factors)14090 Low risk (no TOD or CV risk factors) Very elderly* (≥80 yrs.)160NA Usual blood pressure threshold values for initiation of pharmacological treatment TOD = target organ damage. CHEP, 2015

PopulationSBP <DBP < Diabetes All others < 80 yrs. (including CKD) Very elderly (≥ 80 yrs.) 150 NA Treatment consists of health behaviour ±pharmacological management Recommended Treatment Targets In patients with coronary artery disease be cautious when lowering blood pressure if diastolic blood pressures are < 60mmHg CHEP, 2015

FAQ’s What is the role of hs-CRP? What about Lipoproteins? What is the role of homocysteine? Who needs a Graduated Exercise Stress Test? Who needs referral to a “Specialist?”

Tool for further risk stratification Useful for low to moderate risk patients Good predictor of CVD events Should we do this test regularly? High sensitivity C-reactive protein (hs – CRP)

Provide a more accurate number of “atherogenic” particles Elevated apo B100  elevated LDL or VLDL Lp (a) levels causative for CVD Measured in special cases Not routinely used yet Lipoproteins

No role in the diagnosis of CAD in the absence of clinical findings No predictive value May lead to unnecessary invasive work-up Stress Testing

Complex or difficult to manage Not at target despite maximal meds Excess medication side-effects Development of symptons consistent with CVD Angina TIA Patient’s request When to Refer

64 year old male. Previously well (no PMHx) No family history of premature HD Non-smoker; Minimal ETOH use Took his blood pressure at Walmart 162/80 In the office: 156/78 (BP Tru) Remainder of exam is unremarkable Case # 1

56 year old female On a routine physical: LDL = 5, HDL = 1.02, TG = 2.4 No previous medical history FHx: (+) for HD on father’s side BMI = 29 BP = 146/56 Case # 2

55 year old male in for “executive physical” FHx: (+) for MI (father at 52, mother at 56) Smoker 12 pk-yrs; 8 – 10 drinks / week High stress job Case # 3

Screen patients at any given opportunity Burden of CVD is high Once one traditional risk factor is diagnosed, manage the other risk factors simultaneously Use a risk calculator to determine risk Don’t forget about lifestyle modifications Smoking cessation is the single most important intervention Take Away Points

Thank you….Questions?